EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-SA 4.0

Interaction Between Tumor-Infiltrating Lymphocytes and the PD-1/PD-L1 Pathway in Non-Small Cell Lung Cancer: Implications for Tumor Progression and Immunotherapy Response — A Systematic Review

Sultan Pasha, Rasi Sallang, Leony Octavia

MARAS : Jurnal Penelitian Multidisiplin · 03.06.2026 · 4 (2) · 535-545

DOI: 10.60126/maras.v4i2.1604 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift MARAS : Jurnal Penelitian Multidisiplin, online erschienen am 03.06.2026. Verfasst von Sultan Pasha und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. The interaction between tumor-infiltrating lymphocytes (TILs) and the programmed cell death protein-1/programmed death-ligand 1 (PD-1/PD-L1) pathway plays a critical role in tumor progression and response to immunotherapy. This systematic review evaluated current evidence regarding the prognostic and predictive significance of these immune biomarkers in NSCLC. A systematic search was conducted in PubMed, SpringerLink, and ScienceDirect for studies published between 2018 and 2024. Eligible studies included original human research assessing TIL characteristics, PD-1/PD-L1 expression, and their associations with survival outcomes or responses to immune checkpoint inhibitors. Ten studies met the inclusion criteria. The findings demonstrated that high CD8⁺ TIL infiltration was consistently associated with improved survival and enhanced responsiveness to PD-1/PD-L1 blockade. PD-L1 expression was frequently linked to immune-inflamed tumor phenotypes, although its prognostic value varied across studies. Several studies reported that the combined evaluation of TILs and PD-1/PD-L1 expression provided better predictive accuracy than either biomarker alone. Furthermore, adoptive TIL therapy showed promising clinical activity in patients with PD-1-resistant disease. These findings indicate that the interaction between TILs and the PD-1/PD-L1 pathway is a key determinant of immunotherapy outcomes in NSCLC and may support more effective patient stratification and personalized treatment strategies.

Zitieren

APA

Pasha, S., Sallang, R., & Octavia, L. (2026). Interaction Between Tumor-Infiltrating Lymphocytes and the PD-1/PD-L1 Pathway in Non-Small Cell Lung Cancer: Implications for Tumor Progression and Immunotherapy Response — A Systematic Review. MARAS : Jurnal Penelitian Multidisiplin, 4(2), 535-545. https://doi.org/10.60126/maras.v4i2.1604

Vancouver

Pasha S, Sallang R, Octavia L. Interaction Between Tumor-Infiltrating Lymphocytes and the PD-1/PD-L1 Pathway in Non-Small Cell Lung Cancer: Implications for Tumor Progression and Immunotherapy Response — A Systematic Review. MARAS : Jurnal Penelitian Multidisiplin. 2026;4(2):535-545. doi:10.60126/maras.v4i2.1604

BibTeX
@article{Pasha2026,
  author = {Pasha, Sultan and Sallang, Rasi and Octavia, Leony},
  title = {Interaction Between Tumor-Infiltrating Lymphocytes and the PD-1/PD-L1 Pathway in Non-Small Cell Lung Cancer: Implications for Tumor Progression and Immunotherapy Response — A Systematic Review},
  journal = {MARAS : Jurnal Penelitian Multidisiplin},
  year = {2026},
  volume = {4},
  number = {2},
  pages = {535--545},
  doi = {10.60126/maras.v4i2.1604}
}
Kostenlos starten →